![](/img/cover-not-exists.png)
PD-013Final survival results of a multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer patients refractory to standard therapies (C-TASK FORCE)
Yoshino, T., Kuboki, Y., Nishina, T., Shinozaki, E., Yamazaki, K., Shitara, K., Okamoto, W., Kajiwara, T., Matsumoto, T., Tsushima, T., Mochizuki, N., Fukutani, M., Nakamoto, M., Hasegawa, H., Sugama,Volume:
27
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw200.13
Date:
June, 2016
File:
PDF, 171 KB
2016